Canadian radioisotope developer MDS Nordion of Kanata, Ontario, has been selected by Berlex Canada to supply yttrium-90 chloride sterile solution (Y-90) for use with Berlex's Zevalin radioimmunotherapy indicated for non-Hodgkin's lymphoma (NHL).
Zevalin (ibritumomab tiuxetan) was recently approved by Health Canada, and is indicated for the treatment of adult patients with relapsed or refractory CD20-positive low-grade or follicular B-cell NHL, according to MDS Nordion.
The radioimmunotherapy agent combines the targeting ability of an anti-CD20 monoclonal antibody with the cytotoxic power of beta radiation emitted by the Y-90 isotope. Y-90 is a pure beta emitter, enabling routine outpatient administration, so that patients may return home or to their workplace after treatment, MDS Nordion said.
By AuntMinnie.com staff writers
September 20, 2005
Related Reading
MDS Nordion targets drug discovery, June 28, 2005
MDS Nordion brings Cu-64 to market, June 16, 2005
MDS Nordion, Macrocyclics sign R&D accord, May 26, 2005
MDS hires Hawkins as chief science and technology officer, April 28, 2005
Declining U.S. dollar hurts MDS Life Sciences' Q1, March 11, 2005
Copyright © 2005 AuntMinnie.com
